Status: Not yet recruiting
Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome
The purpose of this Phase I, open-label study is to evaluate the safety and tolerability of intravenous MiraMSC-FS-001 in older adults with mild to moderate frailty syndrome. MiraMSC-FS-001 is an investigational product consisting of allogeneic umbilical cord-derived mesenchymal stem cells (UCMSCs). Eligible participants will receive intravenous administration of MiraMSC-FS-001.
Participants needed: 12
Trial details
Phase: Phase 1Age: 60-85Biological sex: AllType: InterventionalSponsor: Miracle Biomedical Co., Ltd.Updated: Jul 15, 2026
Eligibility criteria
Subjects aged ≥ 60 through ≤ 85 years old. [+2]
Subjects unwill ing or unable to perform any of the assessments required by endp... [+23]